Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021055807 - ACTIVATING PYRUVATE KINASE R

Publication Number WO/2021/055807
Publication Date 25.03.2021
International Application No. PCT/US2020/051579
International Filing Date 18.09.2020
IPC
A61K 31/407 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/436 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
436the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 7/06 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
06Antianaemics
C07D 487/04 2006.01
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
CPC
A61K 31/407
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/436
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
435having six-membered rings with one nitrogen as the only ring hetero atom
4353ortho- or peri-condensed with heterocyclic ring systems
436the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
A61P 7/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
7Drugs for disorders of the blood or the extracellular fluid
06Antianaemics
C07D 519/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
519Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applicants
  • FORMA THERAPEUTICS, INC. [US]/[US]
Inventors
  • ERICSSON, Anna
  • GREEN, Neal
  • GUSTAFSON, Gary
  • LANCIA, David, R.
  • MARSHALL, Gary
  • MITCHEL, Lorna
  • RICHARD, David
  • WANG, Zhongguo
  • FORSYTH, Sanjeev
  • KELLY, Patrick, F.
  • MONDAL, Madhu
  • RIBADENEIRA, Maria
  • SCHROEDER, Patricia
Agents
  • NEY, Joshua, E.
  • BOUDREAUX, William, R.
  • MARSHALL, Ryan, L.
  • SHEREDA, Robert, D.
Priority Data
16/576,36019.09.2019US
16/576,72019.09.2019US
62/704,78528.05.2020US
62/705,10611.06.2020US
62/902,88719.09.2019US
62/906,43726.09.2019US
63/024,43213.05.2020US
63/024,44113.05.2020US
PCT/US19/5202419.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ACTIVATING PYRUVATE KINASE R
(FR) ACTIVATION DE LA PYRUVATE KINASE R
Abstract
(EN)
The compound (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6- tetrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phenylpropan-1-one, or a pharmaceutically acceptable salt thereof, is useful to increase the affinity of hemoglobin for oxygen. Methods and compositions for the treatment of a hemoglobinopathies are provided herein, including certain pharmaceutical compositions for activating PKR.
(FR)
Le composé (S)-1-(5-((2,3-dihydro-[1,4]dioxino[2,3-b]pyridin-7-yl)sulfonyl)-3,4,5,6- tétrahydropyrrolo[3,4-c]pyrroll-2(1H)-yl)-3-hydroxy-2-phénylpropan-1-one, ou un sel pharmaceutiquement acceptable de celui-ci, est utile pour augmenter l'affinité de l'hémoglobine pour l'oxygène. L'invention concerne des méthodes et des compositions pour le traitement d'hémoglobinopathies, notamment certaines compositions pharmaceutiques pour activer la PKR.
Latest bibliographic data on file with the International Bureau